Total Fluid Intake and the Risk of Recurrence in Patients With Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study

To investigate the role of fluid intake from beverages before and after a diagnosis of bladder cancer in relation to the risk of developing bladder cancer recurrence.

Prospective cohort study.

716 patients with non-muscle invasive bladder cancer (NMIBC), who received transurethral resection of a primary bladder tumour (TURBT) and completed self-administrated questionnaires on usual fluid intake from beverages at time of diagnosis (over the year before diagnosis) and during follow-up (over the year after diagnosis), were included. Multivariable Cox regression was used to calculate hazard ratios and 95% confidence intervals of developing recurrent bladder cancer in relation to the intake of total fluid, total alcohol, and individual beverages.

During 2,025 person-years of follow-up, 238 (33%) of the included 716 NMIBC patients developed one or more recurrences of bladder cancer. Total fluid intake before diagnosis was not associated with a first recurrence of bladder cancer when comparing the highest and lowest intake group (HR = 0.98, 95% C.I. 0.70-1.38, p = 0.91). Comparable results were obtained for total fluid intake pre-diagnosis and the risk of developing multiple recurrences of bladder cancer (HR = 1.01, 95% C.I. 0.87-1.19, p = 0.85). A total of 379 of the 716 patients reported on usual fluid intake within 1 year of diagnosis. No significant associations between total fluid intake 1 year after diagnosis and a first recurrence of bladder cancer were found when comparing the highest and lowest intake group (HR = 0.91; 95% C.I. 0.60-1.37, p = 0.65) or with multiple recurrences of bladder cancer (HR = 1.06; 95% C.I. 0.89-1.26, p = 0.54). In addition, total alcohol intake and individual beverages were not associated with bladder cancer recurrence.

The results indicate that an individual's fluid intake from beverages is unlikely to have an important role in bladder cancer recurrence.

Bladder cancer (Amsterdam, Netherlands). 2018 Jul 30*** epublish ***

Sylvia H J Jochems, Frits H M van Osch, Raoul C Reulen, Mitch van Hensbergen, Duncan Nekeman, Sarah J Pirrie, Anke Wesselius, Frederik J van Schooten, Nicholas D James, D Michael A Wallace, Richard T Bryan, K K Cheng, Maurice P Zeegers

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Department of Public Health, Epidemiology and Biostatistics, institute of Applied Health Research, University of Birmingham, UK., School for Nutrition and Translational Research in Metabolism, Maastricht University, The Netherlands.